DMAC vs GD · $157.4M cap vs P/E 22, rev $52.55B
DiaMedica Therapeutics Inc (DMAC) versus General Dynamics Corporation (GD) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
General Dynamics Corporation (GD) is a aerospace & defense company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported GD revenue for 2025-12-31 was $52.55B. Net income was $4.21B. Revenue was up 10.1% from 2024-12-31 to 2025-12-31. GD currently screens at market cap $93.69B and trailing P/E 21.8.
DMAC currently screens at market cap $157.4M. GD currently screens at market cap $93.69B and trailing P/E 21.8.
Not investment advice. Open the DMAC and GD stock pages for the full models.
Not investment advice.